Evidence map›Paper›PMID 32281411›Full record

ReviewExperimental biology and medicine (Maywood, N.J.)2020

Stem cell-based treatment of kidney diseases.

Binbin Pan, Guoping Fan

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Experimental biology and medicine (Maywood, N.J.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Development of Cell Therapies for Renal Disease and Regenerative Medicine.International journal of molecular sciences · 2022
    Review
  3. Review
  4. JMJD3: a critical epigenetic regulator in stem cell fate.Cell communication and signaling : CCS · 2021
    Review
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

Binbin PanDepartment of Nephrology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210029, China.
Guoping FanDepartment of Human Genetics, David Geffen School of Medicine, University of California Los Angeles, CA 90095, USA.ORCID 0000-0001-5235-6410
University of California, Los Angeles · US

Funding

Dissecting molecular pathways underlying Human Overgrowth SyndromeR01DE025474 · NIDCR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FAN, GUOPING · 2016 to 2020
$1.9M
NIDCR NIH HHS R01 DE025474
6 · The paper itself

Abstract

impact statementStem cells hold great promise in regenerative medicine. Pluripotent stem cells have been differentiated into kidney organoids to understand human kidney development and to dissect renal disease mechanisms. Meanwhile, recent studies have explored the treatment of kidney diseases using a variety of cells, including mesenchymal stem cells and renal derivatives. This mini-review discusses the diverse mechanisms underlying current renal disease treatment via stem cell therapy. We postulate that clinical applications of stem cell therapy for kidney diseases can be readily achieved in the near future.

Indexed as

AnimalsCell- and Tissue-Based TherapyHumansKidney DiseasesOrganoidsRegenerative MedicineStem Cell Transplantationacute kidney injurychronic kidney diseaseCytokine therapykidney organoidsmechanism

Identifiers

PMID32281411
PMCPMC7268929
OpenAlexW3015861698

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.